Institutionalized 0 17 0 17 O
women 18 23 18 23 B-gender
with 24 28 24 28 O
subacute 29 37 29 37 O
illnesses 38 47 38 47 O
surviving 48 57 48 57 O
or 58 60 58 60 O
discharged 61 71 61 71 O
in 72 74 72 74 O
< 75 76 75 76 O
3 77 78 77 78 B-upper_bound
years 79 84 79 84 I-upper_bound

Men 0 3 85 88 B-gender
because 4 11 89 96 O
osteoporosis 12 24 97 109 B-chronic_disease
is 25 27 110 112 O
less 28 32 113 117 O
common 33 39 118 124 O
in 40 42 125 127 O
men 43 46 128 131 B-gender

Patients 0 8 132 140 O
with 9 13 141 145 O
a 14 15 146 147 O
calculated 16 26 148 158 B-clinical_variable
creatinine 27 37 159 169 I-clinical_variable
clearance 38 47 170 179 I-clinical_variable
< 48 49 180 181 O
35 50 52 182 184 B-upper_bound
ml 53 55 185 187 I-upper_bound
/ 55 56 187 188 I-upper_bound
min 56 59 188 191 I-upper_bound

Women 0 5 192 197 B-gender
currently 6 15 198 207 O
on 16 18 208 210 O
bisphosphonate 19 33 211 225 B-treatment
, 33 34 225 226 O
denosumab 35 44 227 236 B-treatment
, 44 45 236 237 O
or 46 48 238 240 O
teriparatide 49 61 241 253 B-treatment
therapy 62 69 254 261 I-treatment
or 70 72 262 264 O
who 73 76 265 268 O
have 77 81 269 273 O
been 82 86 274 278 O
on 87 89 279 281 O
a 90 91 282 283 O
bisphosphonate 92 106 284 298 O
for 107 110 299 302 O
greater 111 118 303 310 O
than 119 123 311 315 O
1 124 125 316 317 B-lower_bound
year 126 130 318 322 I-lower_bound
during 131 137 323 329 O
the 138 141 330 333 O
previous 142 150 334 342 B-upper_bound
2 151 152 343 344 I-upper_bound
years 153 158 345 350 I-upper_bound
because 159 166 351 358 O
bisphosphonates 167 182 359 374 B-treatment
are 183 186 375 378 O
long 187 191 379 383 O
acting 192 198 384 390 O

age 0 3 391 394 B-age
≥65 4 7 395 398 O
years 8 13 399 404 I-lower_bound

have 0 4 405 409 O
a 5 6 410 411 O
contraindication 7 23 412 428 O
for 24 27 429 432 O
bisphosphonates 28 43 433 448 B-treatment
( 44 45 449 450 O
allergy 45 52 450 457 O
, 52 53 457 458 O
hypocalcemia 54 66 459 471 B-chronic_disease
) 66 67 471 472 O

initial 0 7 473 480 O
ZEST 8 12 481 485 O
1 13 14 486 487 O
study 15 20 488 493 O
only 21 25 494 498 O
included 26 34 499 507 O
women 35 40 508 513 B-gender

osteoporosis 0 12 514 526 B-chronic_disease
by 13 15 527 529 O
axial 16 21 530 535 O
bone 22 26 536 540 O
density 27 34 541 548 O
( 35 36 549 550 O
spine 36 41 550 555 O
, 41 42 555 556 O
hip 43 46 557 560 O
or 47 49 561 563 O
forearm 50 57 564 571 O
bone 58 62 572 576 B-clinical_variable
mineral 63 70 577 584 I-clinical_variable
density 71 78 585 592 I-clinical_variable
( 79 80 593 594 I-clinical_variable
BMD 80 83 594 597 I-clinical_variable
) 83 84 597 598 I-clinical_variable
T 85 86 599 600 I-clinical_variable
- 86 87 600 601 I-clinical_variable
score 87 92 601 606 I-clinical_variable
≤ 93 94 607 608 O
-2.5 95 99 609 613 O
SD 100 102 614 616 I-upper_bound
) 102 103 616 617 O

women 0 5 618 623 B-gender

would 0 5 624 629 O
be 6 8 630 632 O
treated 9 16 633 640 O
based 17 22 641 646 O
on 23 25 647 649 O
FRAX 26 30 650 654 O
National 31 39 655 663 O
Osteoporosis 40 52 664 676 O
Foundation 53 63 677 687 O
( 64 65 688 689 O
NOF 65 68 689 692 O
) 68 69 692 693 O
treatment 70 79 694 703 O
thresholds 80 90 704 714 O
of 91 93 715 717 O
a 94 95 718 719 O
10 96 98 720 722 O
year 99 103 723 727 O
risk 104 108 728 732 O
of 109 111 733 735 O
≥ 112 113 736 737 O
20 114 116 738 740 B-lower_bound
% 116 117 740 741 I-lower_bound
for 118 121 742 745 O
a 122 123 746 747 O
major 124 129 748 753 O
osteoporotic 130 142 754 766 O
fracture 143 151 767 775 O
or 152 154 776 778 O
≥ 155 156 779 780 O
3 157 158 781 782 B-lower_bound
% 158 159 782 783 I-lower_bound
for 160 163 784 787 O
hip 164 167 788 791 O
fracture 168 176 792 800 O
using 177 182 801 806 O
femoral 183 190 807 814 B-treatment
neck 191 195 815 819 I-treatment
BMD 196 199 820 823 I-treatment

